Applied Behavior Analysis therapy faces scrutiny over safety and costs

Applied Behavior Analysis (ABA), a widely used therapy for children with autism, is facing increasing scrutiny from health officials and lawmakers due to concerns regarding its effectiveness and potential harm. Critics, including Ari Ne’eman of the Harvard T. H. Chan School of Public Health, argue that the system of rewards and punishments can have negative mental health consequences and may crowd out more effective treatments. There are also concerns regarding the intensity of the therapy, with some providers recommending up to 40 hours a week for very young children.

The industry has seen a massive influx of private equity investment, with firms acquiring 23 of the 50 largest ABA providers in the United States. This has coincided with a significant rise in Medicaid spending; analysis indicates that Medicaid billing for ABA reached nearly $7 billion over six years, an amount exceeding the total U.S. expenditure on autism research and programs over the last 20 years.

In response to these developments and recent federal audits, several states are considering regulatory crackdowns. Proposed measures include capping the amount of ABA a child can receive, limiting provider billing, and imposing stricter standards on clinics. Additionally, debates are emerging in statehouses regarding the political spending of the ABA industry and efforts by providers to influence public school policies.